Aurora Financial Journal

QuidelOrtho Corporation (QDEL)

NASDAQ · Health care · In Vitro & In Vivo Diagnostic Substances · Financial statements, TTM figures and earnings dates

QuidelOrtho Corporation reported revenue of $2.67B over the trailing twelve months ended June 28, 2026, with net income of −$1.05B. Annual financial statements are available for fiscal years 2020 to 2025, taken from the company's filings with the SEC. The next quarterly results release is estimated for November 4, 2026, based on the company's filing history.

Open interactive financials →

Key financials

USDTTM
2026-06-28
FY2025
2025-12-28
FY2024
2024-12-29
FY2023
2023-12-31
FY2022
2023-01-01
FY2021
2022-01-02
Income statement
Revenue$2.67B$2.73B$2.78B$3.00B$3.27B$1.70B
Operating income−$824.7M−$919.2M−$1.96B$139.1M$843.7M$906.0M
Net income−$1.05B−$1.13B−$2.05B−$10.1M$548.7M$704.2M
Diluted EPS−$15.43−$16.69−$30.54−$0.15$9.56$16.43
Cash flow
Operating cash flow−$57.2M$105.2M$83.0M$280.2M$885.3M$805.9M
Capital expenditure$154.0M$188.2M$195.1M$209.3M$140.9M$292.8M
Free cash flow−$211.2M−$83.0M−$112.1M$70.9M$744.4M$513.1M
Balance sheet
Cash and equivalents$123.4M$169.8M$98.3M$118.9M$292.9M$802.8M
Total assets$5.72B$5.77B$6.42B$8.56B$8.86B$2.43B
Total liabilities$3.94B$3.85B$3.44B$3.56B$3.92B$501.0M
Total debt$2.89B$2.70B$2.49B$2.42B$2.65B$1.0M
Shareholders' equity$1.77B$1.92B$2.98B$5.01B$4.93B$1.93B

TTM = trailing twelve months (balance-sheet items at the latest quarter end). Figures in USD as reported; per-share data adjusted for stock splits.

Annual reports

More on the interactive page

The full QDEL page on Aurora Financial Journal includes every fiscal year since the company began filing structured data, income statement, balance sheet and cash flow statement line by line, the statements exactly as filed with the SEC, charts for every measure, valuation multiples (P/E, P/S, P/B), live price charts and the earnings calendar.

Open QDEL financials →